IXHL Stock Catalyst: Incannex Healthcare Completes US Phase 2 Trial for OSA Drug Candidate

Jul 21, 2025 · 4:00am ET

The trial focused on a dual-mechanism drug targeting Obstructive Sleep Apnea.

Max move

+54.6%

High of day $29.75

Sparker timei

4:00am ET

IXHL · Jul 21, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Incannex Healthcare Inc. (Nasdaq: IXHL) has concluded its Phase 2 clinical trial in the United States for a drug candidate designed to treat Obstructive Sleep Apnea (OSA). The trial evaluated the efficacy and safety of the dual-mechanism drug.

The company did not release specific data or outcomes from the trial at this time. Incannex Healthcare has a free float of 302,182,000 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time IXHL sparks.

Download Sniper App →

Catch the next IXHL-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →